Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5825633 | Clinical Therapeutics | 2013 | 8 Pages |
Abstract
The results showed that despite the different strengths of the 2 imatinib formations, the test and reference formulations both met the regulatory criteria for pharmacokinetic equivalence at a dose of imatinib 400 mg in these healthy Korean male subjects. Both imatinib formulations seemed to be generally well tolerated. ClinicalTrials.gov identifier: NCT01270984.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Kyoung-Ah PhD, Shin Jung PhD, Chin PhD, Ji-Young MD, PhD,